全文获取类型
收费全文 | 3423185篇 |
免费 | 253043篇 |
国内免费 | 6054篇 |
专业分类
耳鼻咽喉 | 46987篇 |
儿科学 | 112326篇 |
妇产科学 | 94040篇 |
基础医学 | 494776篇 |
口腔科学 | 98201篇 |
临床医学 | 311430篇 |
内科学 | 657229篇 |
皮肤病学 | 76982篇 |
神经病学 | 270274篇 |
特种医学 | 129013篇 |
外国民族医学 | 693篇 |
外科学 | 516713篇 |
综合类 | 75797篇 |
现状与发展 | 12篇 |
一般理论 | 1255篇 |
预防医学 | 265263篇 |
眼科学 | 82474篇 |
药学 | 253891篇 |
11篇 | |
中国医学 | 7314篇 |
肿瘤学 | 187601篇 |
出版年
2019年 | 27797篇 |
2018年 | 39066篇 |
2017年 | 29490篇 |
2016年 | 32942篇 |
2015年 | 37206篇 |
2014年 | 52433篇 |
2013年 | 78254篇 |
2012年 | 107932篇 |
2011年 | 114420篇 |
2010年 | 68259篇 |
2009年 | 64033篇 |
2008年 | 106821篇 |
2007年 | 113788篇 |
2006年 | 114943篇 |
2005年 | 110937篇 |
2004年 | 106713篇 |
2003年 | 102182篇 |
2002年 | 98611篇 |
2001年 | 162760篇 |
2000年 | 166936篇 |
1999年 | 139499篇 |
1998年 | 37594篇 |
1997年 | 32492篇 |
1996年 | 32692篇 |
1995年 | 33027篇 |
1994年 | 30409篇 |
1993年 | 28418篇 |
1992年 | 108087篇 |
1991年 | 105184篇 |
1990年 | 101892篇 |
1989年 | 98324篇 |
1988年 | 90137篇 |
1987年 | 88245篇 |
1986年 | 83003篇 |
1985年 | 79463篇 |
1984年 | 58926篇 |
1983年 | 50144篇 |
1982年 | 29226篇 |
1979年 | 53574篇 |
1978年 | 37759篇 |
1977年 | 31649篇 |
1976年 | 30036篇 |
1975年 | 31953篇 |
1974年 | 38760篇 |
1973年 | 37118篇 |
1972年 | 34693篇 |
1971年 | 32595篇 |
1970年 | 30241篇 |
1969年 | 28594篇 |
1968年 | 26448篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
3.
S. Liu A. E. Patanwala J. M. Naylor N. Levy R. Knaggs J. A. Stevens B. Bugeja D. Begley K. E. Khor E. Lau R. Allen S. Adie J. Penm 《Anaesthesia》2023,78(10):1237-1248
Modified-release opioids are often prescribed for the management of moderate to severe acute pain following total hip and knee arthroplasty, despite recommendations against their use due to increasing concerns regarding harm. The primary objective of this multicentre study was to examine the impact of modified-release opioid use on the incidence of opioid-related adverse events compared with immediate-release opioid use, among adult inpatients following total hip or knee arthroplasty. Data for total hip and knee arthroplasty inpatients receiving an opioid analgesic for postoperative analgesia during hospitalisation were collected from electronic medical records of three tertiary metropolitan hospitals in Australia. The primary outcome was the incidence of opioid-related adverse events during hospital admission. Patients who received modified with or without immediate-release opioids were matched to those receiving immediate-release opioids only (1:1) using nearest neighbour propensity score matching with patient and clinical characteristics as covariates. This included total opioid dose received. In the matched cohorts, patients given modified-release opioids (n = 347) experienced a higher incidence of opioid-related adverse events overall, compared with those given immediate-release opioids only (20.5%, 71/347 vs. 12.7%, 44/347; difference in proportions 7.8% [95%CI 2.3–13.3%]). Modified-release opioid use was associated with an increased risk of harm when used for acute pain during hospitalisation after total hip or knee arthroplasty. 相似文献
4.
Marco N. Iannone Stefano Stucchi Elia A. Turolla Chiara Beretta Samuele Ciceri Clizia Chinello Lisa Pagani Sergio Todde Patrizia Ferraboschi 《Journal of labelled compounds & radiopharmaceuticals》2022,65(3):48-62
In the last decade, the development of new radiopharmaceuticals for the imaging and therapy of prostate cancer has been a highly active and important area of research, especially focusing on the prostate-specific membrane antigen (PSMA), an antigen which is upregulated in prostate, as well as in other tumor cells. A large variety of PSMA ligands have been radiolabeled, to date. Among the various derivatives, PSMA-617 resulted to be one of the most interesting in terms of interaction with the antigen and clinical properties, and its lutetium-177 labeled version has recently been approved by regulatory agencies for therapeutic purposes. For this reasons, the radiolabeling with fluorine-18 of a PSMA-617 derivative might be of interest. Beside other methodologies to radiolabel macromolecules with fluorine-18, the “click-chemistry” approach resulted to be very useful, and the copper-catalyzed azide-alkyne cycloaddition (CuAAC) is considered one of most efficient and reliable. This paper proposes the synthesis of a suitable precursor for the radiolabeling with fluorine-18 of a new PSMA-617 derivative. The whole radiosynthetic procedure has been fully automated, and the final product, which proved to be stable in plasma, has been obtained with radiochemical yield and purity suitable for subsequent preclinical studies. 相似文献
5.
6.
Maja Popovic Gorana Matovina-Brko Masa Jovic Lazar S Popovic 《World journal of clinical oncology》2022,13(1):28-38
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with inter mediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozan tinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment. 相似文献
7.
Rozhkov V. P. Trifonov M. I. Soroko S. I. 《Neuroscience and behavioral physiology》2022,52(3):383-394
Neuroscience and Behavioral Physiology - We present here results from analysis of the formation of brain bioelectrical activity in children and adolescents living in the northern region of Russia... 相似文献
8.
9.
Edwin van der Pol Joshua A. Welsh Rienk Nieuwland 《Journal of thrombosis and haemostasis》2022,20(1):245-251
The Extracellular Vesicle Flow Cytometry Working Group ( http://www.evflowcytometry.org ) is formed by members of the International Society for Extracellular Vesicles (ISEV), the International Society for Advancement of Cytometry (ISAC), and the International Society on Thrombosis and Haemostasis (ISTH). This working group of flow cytometry experts develops guidelines for best practices regarding flow cytometry detection of extracellular vesicles. To improve rigor and standardization, this working group published a framework outlining the minimal information to report about a flow cytometry experiment on extracellular vesicles (MIFlowCyt-EV) in the Journal of Extracellular Vesicles, the ISEV journal, in 2020. In parallel, an article explaining MIFlowCyt-EV was published in Cytometry Part A, one of the ISAC journals, and now will be introduced to the ISTH as an SSC Communication in the Journal of Thrombosis and Haemostasis. The goal of this SSC Communication is to explain why flow cytometry is becoming the instrument of choice to characterize single extracellular vesicles, the obstacles that have been identified and (mostly) overcome by developing procedures to calibrate flow cytometers, and the relevance of reporting minimal information to improve reliability and reproducibility of experiments in which flow cytometers are used for characterization of extracellular vesicles. 相似文献
10.
Troppmair Teresa Egger J. Krösbacher A. Zanvettor A. Schinnerl A. Neumayr A. Baubin M. 《Der Anaesthesist》2022,71(4):272-280
Die Anaesthesiologie - Die Qualität eines Rettungssystems zeichnet sich auch durch den effizienten Einsatz seiner personellen und Fahrzeugressourcen aus. So können im berechtigten Fall... 相似文献